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undertaken to rationalize prescribing in an emergency de-
partment (ED). 
METHODS: The annual census of our ED is 50,000 pa-
tients, 40% of whom receive prescription drugs. Prescrip-
tions written by a total of 57 physicians were collected
during 5 days before (P1) a 45-day intervention, then 5
days immediately after (P2) and 12 days, 3 years later
(P3). The intervention was an educational program with
emphasis on contraindications and adverse effects. Con-
forming indications were either established (E) (mainly
rheumatological) or admitted (A) but controversial (trauma,
ENT). For the latter, NSAIDs may be withheld. Between
P1 and P2 all E&A indications were shown. Between P2
and P3, only the E indications were available. Prescribing
errors were the main endpoint. 
RESULTS: NSAIDs were prescribed for 37/434 patients
(8.5%), 42/414 (10%), and 12/583 (2%), respectively
(p  0.0001). Between P1 and P2, prescribing errors de-
creased from 19% to 14% (p  0.76). In P3, 1 was
found. Between P1 and P3, conforming prescriptions in-
creased from 81% to 92% (p  0.66): NSAIDs decreased
for trauma (50% to 8%; p  0.02) and increased for
rheumatology (19% to 42%; p  0.14). Duration of
treatment decreased from 8.0–4.0 days to 6.0–3.0 days
(p  0.07). 
CONCLUSIONS: Overall NSAIDs as well as incorrect
prescribing decreased after an intervention. However, 1)
“Soft indications” stimulated prescribing; 2) Its curbing
was obtained by a limited list between P2 and P3. This
approach may be applied to other controversial drugs.
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Significant opportunities for patient safety are potentially
achievable with the introduction of the cycloxygenase-2
(COX-2) inhibitors. Unfortunately, constrained health-
care budgets may limit their use. 
OBJECTIVE: To describe a NSAID therapeutic portfolio
that maximizes medical benefits, but does not increase
existing healthcare costs. 
METHODS: A meta-heuristic assisted optimization of a
typical HMO’s NSAID portfolio after the introduction of
celecoxib 200 mg QD was conducted using linear pro-
gramming techniques. Current NSAID  antiulcerant us-
age and the cost of managing NSAID related gastropathy
was derived from a large HMO. Background antiulcerant
usage was established from an equivalent non-NSAID ex-
posed arthritis population. The probabilities of NSAID
related gastrointestinal events were derived from clinical
trials and the literature. Decreased hospitalized gas-
trointestinal events without increasing the overall health
budget were defined as the optimization criteria. Antiul-
cerant usage was not allowed to decrease below the back-
ground rate.
RESULTS: Assuming an average risk of NSAID-induced
GI toxicity and 150 days/year of therapy, the average
cost/patient/year for NSAID therapy and related adverse
events would be $366. If celecoxib is introduced into the
healthcare system, 74% of patients could be switched to
the agent without increasing the overall budget, provided
that the remaining patients were distributed as follows:
13% generic ibuprofen; 9% generic NSAID  H2 block-
ers or prostaglandins; and 4% generic NSAID  PPI.
During a 1-year period, this distribution of agents would
result in 29 fewer physician visits and two less hospital-
ization per 1000 patients. 
CONCLUSIONS: These results indicate that by optimiz-
ing the distribution of NSAIDs utilized within a HMO, a
significant number of osteoarthritic patients can receive
safer COX-2 specific compounds such as celecoxib with-
out increasing the total budget.
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OBJECTIVE: To provide a clinically meaningful inter-
pretation of improvements in WOMAC scores among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC), PtGA & PhGA were administered at
baseline and week 12. WOMAC is a 24-item instrument
that contains three domains: pain, stiffness, and physical
functioning and a summary score. PtGA & PhGA were
measured on the following 5-point scale: very good, good,
fair, poor, or very poor. Change scores were computed by
subtracting patient’s baseline from week 12 follow-up
scores. Responsiveness was estimated as the mean change
score corresponding to each level of PtGA or PhGA im-
provement. 
RESULTS: At week 12, the number of patients experi-
encing improvements in PtGA and PhGA were: 1108 and
1158 for one-level, 708 and 745 for two-levels, and 368
and 311 for three or more levels. The average improve-
ment of WOMAC domain and total scores among pa-
tients experiencing one, two, or three or more levels of
PtGA improvement were 2.3, 4.4, 6.5 for pain, 1.0, 1.7,
2.5 for stiffness, 7.3, 13.9, 20.4 for physical functioning,
and 10.1, 18.7, 27.4 for total WOMAC score. A similar
responsiveness was found between average WOMAC
scores and PhGA improvement, which were 2.3, 4.4, 6.6
for pain, 1.0, 1.7, 2.5 for stiffness, 7.5, 13.6, 21.0 for
physical-functioning, and 10.3, 18.6, 27.9 for total
WOMAC score. 
